Frontier IP first Portuguese spin out developing novel technologies

Frontier IP Chief Executive Officer Neil Crabb said: “We’re very pleased to take a material stake in a company developing such ground-breaking technology. Paper-E has already attracted strong interest from a wide range of potential partners.”

Frontier IP (LON:FIPP), which specialises in commercialising university intellectual property, today announced its first Portuguese spin out NTPE¹ , in which it is taking a 31.8 per cent stake.

NTPE is developing novel technology called Paper-E to print electronic circuits, sensors and semiconductors onto any cellulose-based paper and is a result of the Group’s formal relationship with the Universidade Nova de Lisboa Faculty of Science and Technology (“FCT NOVA”).

The technology replaces the silicon used in electronics with eco-friendly metal oxides and cellulose, to create “inks” that can be used in specially adapted printers and printing technologies, such as ink-jet heads. It has been developed by a research team led by Professors Rodrigo Martins and Elvira Fortunato from FCT Nova. NTPE will develop and commercialise its work.

There is a huge range of industrial applications for the technology, including paper-based diagnostic kits, smart packaging, logistics, and many others.

Because it is possible to store data in the cellulose, there are potential applications in fraud prevention – for example, to replace microchips with electronic pages in passports and other identity documents which need to be tracked.

Non-governmental organisations in low and middle-income countries are keen to explore the technology for use in real time lab-on-paper diagnostic solutions. This is because it does not need a power source and results can be shared via mobile phones. The technology can also produce disposable smart electronic interfaces for near field and Radio-frequency identification, RFID, communications.

The technology has been developed within a research group from the materials department of FCT NOVA, national scientific research centre Cenimat and the Centre of Excellence in Microelectronics, Optoelectronics and Processes.

They bring together more than 65 researchers dedicated to new approaches in electronic materials and applying them to build novel electronic devices and systems. Cenimat collaborates with companies and research organisations such as Samsung, Merck, ETRI, Flexenable, Osram, LG, Solvay, Eurocat, the Navigator Company, Clara Saúde, INCM, and others.

The research team was shortlisted by the European Patent Office (“EPO”) in the Research category of its Inventor of the Year Awards 2016.

At the time, the then EPO president Benoît Battistelli said: “The paper-based microchips developed by Elvira Fortunato and her team have the potential to bring smart computer technology to entirely new areas of daily life.”

NTPE has been incorporated to develop and commercialise their work.

Frontier IP aims to be the leading commercial partner to Portuguese universities. As well as FCT NOVA, the company also has a range of formal and informal relationships with local universities and companies.

Professor Rodrigo Martins said: “From dreams to reality: this has been such a great journey to develop new eco-sustainable products using Paper-E capable of revolutionising the market for a broad range of existing and emerging fields. FCT NOVA and Frontier IP are on the frontline of commercialising Portuguese technology.”

¹The Company is incorporated in Portugal under the full name of: NTPE Research, Development and Marketing of Transistors and Electronic Paper Biosensors.

Click to view all articles for the EPIC:
Or click to view the full company profile:
    Facebook
    Twitter
    LinkedIn
    Frontier IP Group Plc

    More articles like this

    Frontier IP Group Plc

    Animal Lovers and Zoonotic Diseases: 5 Things to Know

    Zoonotic diseases, or zoonoses, are on the rise. That may first bring to mind exotic diseases like Ebola, but the reality is that many zoonotic infections happen closer to home, often during everyday activities. In 2018,

    Frontier IP Group Plc

    AI-based initiatives catalyzing immunotherapy in 2018

    Artificial intelligence (AI) has been dynamically changing the field of drug discovery in several areas, including immunotherapy, oncotherapy, neurological disease, and many more. Described here is an ensemble of the initiatives in place to advance the field of

    Frontier IP Group Plc

    Frontier IP Group Plc appoint N+1 Singer as sole broker

    Frontier IP Group PLC (LON:FIPP), a specialist in commercialising university intellectual property, today announced the appointment of Nplus1 Singer Advisory LLP as the Group’s sole broker with immediate effect. Allenby Capital Limited remains the Group’s Nominated Adviser.

    Frontier IP Group Plc

    Britain’s university spinout sector is thriving

    They are among Britain’s greatest national treasures and a powerful engine of ideas and innovation for the nation’s booming technology industry. But how good are UK universities at commercialising the research and expertise which springs from

    Frontier IP Group Plc

    Exscientia CEO explains how AI is transforming drug discovery

    In recent decades a strange confluence has formed in the pharmaceutical industry. A range of powerful technologies have brought enormous new capabilities to the sector, productivity has been simultaneously declining. Deloitte’s Centre for Health Solutions estimates that projected returns on investment

    Frontier IP Group Plc

    How technology is revolutionising the healthcare industry

    A technology revolution is transforming the healthcare industry, changing everything from how patients are diagnosed and treated to our battle against some of the world’s most serious diseases. It’s a revolution fuelled by new sources of

    Frontier IP Group Plc

    Artificial Intelligence will Revolutionise Drug Discovery

    New technologies are making their way into the healthcare industry and healthcare providers are already experimenting with advances such as smart pill technology, 3D-printed medication, and mobile apps. But probably the biggest potential lies in artificial intelligence

    Frontier IP Group Plc

    Rallybio forges joint venture with U.K. tech firm

    A Farmington biotech startup formed by a trio of former top Alexion executives said it is working on drug discovery with an artificial intelligence company in the United Kingdom. Rallybio, focused on rare diseases, has not yet publicly

    Frontier IP Group Plc

    What is leptospirosis and how can it harm us and our pets?

    Recently reported cases of the often fatal bacterial infection leptospirosis in dogs in Sydney have raised the issue of animal diseases that also affect humans. This zoonotic disease is spread by rats and other rodents. However, this

    Frontier IP Group Plc

    The Robot Uprising Is Here

    The robot uprising is inevitable. Take the world’s first raspberry-picking robot, an autonomous machine that’s in development by Fieldwork Robotics at the University of Plymouth in the UK. This fruit-picking Terminator, so to speak, was developed for

    Frontier IP Group Plc

    The UK’s 50 Most Disruptive Companies Revealed

    After receiving applications from a wide range of early stage and more established companies from across industries, the initial list was whittled down to 100 by D/SRUPTION. The list was then submitted to an expert judging

    Frontier IP Group Plc

    Artificial intelligence in the world of drug discovery

    Charlotte Walker-Osborn, a Partner and Head of Technology Sector (International) at global law-firm Eversheds Sutherland and a legal expert in technology law, explains some of the challenges and potential future of artificial intelligence (AI) in the

    Frontier IP Group Plc

    11 diseases which can cause infection

    Illnesses that can pass from animals to humans are known as zoonotic. They’re surprisingly common: More than six out of every 10 known infectious diseases in people are actually contracted from animals, according to the CDC.